Dashboard
1
High Management Efficiency with a high ROCE of 14.23%
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Healthy long term growth as Net Sales has grown by an annual rate of 90.08% and Operating profit at 61.29%
4
Negative results in May 25
5
With ROCE of 17.95%, it has a very attractive valuation with a 1.38 Enterprise value to Capital Employed
6
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,055 Million (Micro Cap)
9.00
NA
0.00%
0.24
13.06%
1.25
Revenue and Profits:
Net Sales:
1,543 Million
(Quarterly Results - Feb 2024)
Net Profit:
97 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.84%
0%
8.84%
6 Months
-3.67%
0%
-3.67%
1 Year
3.7%
0%
3.7%
2 Years
13.71%
0%
13.71%
3 Years
-4.13%
0%
-4.13%
4 Years
-20.45%
0%
-20.45%
5 Years
0%
0%
0.0%
Muromachi Chemicals, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
90.08%
EBIT Growth (5y)
61.29%
EBIT to Interest (avg)
19.40
Debt to EBITDA (avg)
1.19
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
1.65
Tax Ratio
31.07%
Dividend Payout Ratio
41.38%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.97%
ROE (avg)
16.83%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
1.44
EV to EBIT
7.69
EV to EBITDA
5.95
EV to Capital Employed
1.38
EV to Sales
0.58
PEG Ratio
0.10
Dividend Yield
NA
ROCE (Latest)
17.95%
ROE (Latest)
15.40%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Feb'24 - YoY
Feb'24
Feb'23
Change(%)
Net Sales
1,542.70
1,503.40
2.61%
Operating Profit (PBDIT) excl Other Income
172.90
132.10
30.89%
Interest
4.70
4.60
2.17%
Exceptional Items
1.50
1.80
-16.67%
Consolidate Net Profit
97.30
80.90
20.27%
Operating Profit Margin (Excl OI)
88.90%
66.50%
2.24%
USD in Million.
Net Sales
YoY Growth in quarter ended Feb 2024 is 2.61% vs 17.47% in Feb 2023
Consolidated Net Profit
YoY Growth in quarter ended Feb 2024 is 20.27% vs 114.02% in Feb 2023
Annual Results Snapshot (Consolidated) - May'23
May'23
May'22
Change(%)
Net Sales
6,291.40
5,681.10
10.74%
Operating Profit (PBDIT) excl Other Income
494.00
542.50
-8.94%
Interest
17.70
17.00
4.12%
Exceptional Items
6.90
3.80
81.58%
Consolidate Net Profit
256.30
456.30
-43.83%
Operating Profit Margin (Excl OI)
58.70%
77.00%
-1.83%
USD in Million.
Net Sales
YoY Growth in year ended May 2023 is 10.74% vs 14.93% in May 2022
Consolidated Net Profit
YoY Growth in year ended May 2023 is -43.83% vs 152.52% in May 2022
About Muromachi Chemicals, Inc. 
Muromachi Chemicals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






